Dana-Farber/Boston Children's Named the Top Pediatric Cancer Program in the Nation for 2026-2027 - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Dana-Farber/Boston Children's Named the Top Pediatric Cancer Program in the Nation for 2026-2027

U.S. News & World Report has recognized Dana-Farber/Boston Children’s Cancer and Blood Disorders Center as the #1 pediatric cancer program in the nation in its 2026-2027 Best Children’s Hospitals report.

  • By

  • September 15, 2026

  • 3 min

Share

  • 1

    Dana-Farber/Boston Children’s Cancer and Blood Disorders Center is ranked #1 pediatric cancer program in the nation for 2026-2027 by U.S. News & World Report.

  • 2

    The center has been among the top three pediatric cancer centers since the rankings began in 2007, with the most #1 rankings.

  • 3

    The program combines expertise from two renowned institutions, providing comprehensive care for children with cancer since 1947.

  • 4

    U.S. News evaluated 114 children’s hospitals, focusing on clinical outcomes and quality of resources related to patient care.

  • 5

    The recognition reflects the center's commitment to clinical excellence, patient safety, and transformative research in pediatric oncology.

Original Source(s)

Dana-Farber/Boston Children's Named the Top Pediatric Cancer Program in the Nation for 2026-2027

  • by

  • September 15, 2026

Related Content

CAR T Before Surgery Improves Glioblastoma Control in Mice

Study finds that tumor resection creates a more immunosuppressive environment and that earlier CAR T cell treatment prolongs survival

  • September 7, 2026

  • 3 min
AI-Designed Binder Improves CAR T Cell Activity in Mice

Researchers screened 1,758 de novo protein binders and identified design features that influence CAR T cell activation, specificity, and tumor control

  • September 15, 2026

  • 3 min
Retraction Note: TWIST1 activates cancer stem cell marker genes to promote epithelial‑mesenchymal transition and tumorigenesis in esophageal squamous cell carcinoma